ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Acronyms ARGOS
- Sponsors AbbVie; Allergan
- 09 Aug 2024 Status changed from recruiting to completed.
- 12 Apr 2024 Planned End Date changed from 30 Jun 2024 to 23 Jul 2024.
- 12 Apr 2024 Planned primary completion date changed from 30 Jun 2024 to 23 Jul 2024.